Veru Inc. (VERU) stock
Close on Nov 12, 2026Market cap $36.15MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $36.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.27
- Dividend yield
- –
- Free cash flow yield
- -72.05%
Fundamentals
- Net income
- -$13.61M
- EPS, diluted
- -$0.58
- Free cash flow
- -$26.04M
- Book value per share
- $1.23
- Diluted shares
- 23M
Trading
- Next earnings
- Dec 16, 2026 (estimated, before the open)
- Previous close
- $2.14
- Open
- $2.10
- Day's range
- $2.08 – $2.15
- Volume
- 91,575
- Average volume (20 days)
- 126,698
- Beta (5 years)
- 0.04
- 52-week range
- $2.04 – $7.33
- RSI (14 days)
- 41.4
- Volatility (1 year)
- 108.1%
- Relative volume
- 0.41×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VERU | S&P 500 | Difference | VERU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.9% | -2.7% | −9.2 pts | ||
| 3 months | -22.6% | -1.7% | −20.9 pts | ||
| Year to date | -0.9% | +11.9% | −12.8 pts | ||
| 1 year | -22.3% | +12.0% | −34.3 pts | ||
| 3 years | -76.9% | +78.2% | −155.1 pts | -38.6% | +21.2% |
| 5 years | -97.8% | +73.2% | −171.1 pts | -53.5% | +11.6% |
| 10 years | -74.8% | +309.6% | −384.4 pts | -12.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Veru filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- Results
- News
About Veru
Pharmaceutical Preparations
Veru Inc. is a clinical-stage biopharmaceutical company that develops treatments for cardiometabolic and inflammatory diseases. The firm focuses on two drug candidates: enobosarm and sabizabulin. Enobosarm is an oral selective androgen receptor modulator designed to preserve lean muscle tissue and increase fat reduction in individuals undergoing weight-loss therapy with GLP-1 receptor agonists. Sabizabulin is an oral microtubule disruptor intended to diminish vascular inflammation in patients with atherosclerotic cardiovascular conditions. Through these investigational programs, the company targets overweight individuals, older adults with obesity at risk of muscle loss, and patients diagnosed with coronary artery disease.
Company profile, executives and historyVeru stock: common questions
What is Veru's stock price?
VERU closed at $2.12 on Nov 12, 2026, down 0.93% on the day. Over the past 52 weeks it traded between $2.04 and $7.33.
What is Veru's market cap?
Veru was worth $36.15M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VERU's P/E ratio?
Veru lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.58), so it has no meaningful P/E ratio.
Does Veru pay a dividend?
No. Veru has not paid a cash dividend over the last twelve months.
When does Veru report earnings next?
Veru is expected to report Q4 FY2026 results on Dec 16, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has VERU stock performed over the past year?
Including dividends, VERU returned -22.3% over the past year, against +12.0% for the S&P 500.
How many VERU shares are sold short?
1M shares were sold short at the latest FINRA report, 110.83% of the float, or 13.3 days of average trading volume.
Who are Veru's competitors?
Companies most similar to Veru by business, industry and size include MTVA, MANE, GPCR, VKTX, VTVT.
See a number that looks wrong?